SCHEMBL6686980

SCHEMBL6686980

CCC1SC(=O)N(CCc2ccc(NC(=O)c3ccncc3)cc2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
FLT1 P17948 1/20 0.45
KDR P35968 1/20 0.45
NAMPT P43490 1/20 0.44
PDE4A P27815 4/20 0.44
PDE4B Q07343 4/20 0.44
PDE4C Q08493 4/20 0.44
PDE4D Q08499 4/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
POLB P06746 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 2/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689567 0.92 PDE4D (0.49) LMNAMAPK1HTTSMN1; SMN2L3MBTL1
SCHEMBL146309 0.91 ABCG2 (0.52) LMNAMAPK1HTTSMN1; SMN2PDE4A
SCHEMBL6659018 0.89 PDE4A (0.46) SMN1; SMN2FLT1KDRPDE4APDE4B
SCHEMBL7802039 0.88 PDE4D (0.47) LMNASMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL7800586 0.88 PDE4D (0.47) PDE4APDE4BPDE4CPDE4D
SCHEMBL7798492 0.88 PDE4D (0.47) PDE4APDE4BPDE4CPDE4D
SCHEMBL6655142 0.88 NPC1 (0.46) LMNASMN1; SMN2FLT1KDRPDE4A
SCHEMBL7802858 0.88 PDE4D (0.47) HTTSMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL6657136 0.88 SMN1; SMN2 (0.49) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6689832 0.88 PDE4D (0.45) LMNAMAPK1HTTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B LMNA 2603/4885MAPK1 1267/4885HTT 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.